Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRCA2 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HRD + BRCA2 mutation (7)

BRCA2 mutation + HR positive (3)

HR positive + BRCA2 mutation (3)

BRCA2 mutation + HER-2 negative (2)

HR negative + BRCA2 mutation (2)

ALK rearrangement + BRCA2 F2801fs (1)

BRCA1 mutation + BRCA2 mutation + TMB-H (1)

BRCA2 deletion + ATM mutation (1)

BRCA2 mutation + AKR1C3 overexpression (1)

BRCA2 mutation + ER positive (1)

BRCA2 mutation + ER positive + PGR positive (1)

BRCA2 mutation + RB1 deletion (1)

BRCA2 mutation + TMB-H (1)

BRCA2 mutation + TMB-L (1)

HR positive + BRCA2 mutation + PALB2 mutation (1)

ER positive + BRCA2 mutation (0)

HRD + BRCA2 mutation (7)

BRCA2 mutation + HR positive (3)

HR positive + BRCA2 mutation (3)

BRCA2 mutation + HER-2 negative (2)

HR negative + BRCA2 mutation (2)

ALK rearrangement + BRCA2 F2801fs (1)

BRCA1 mutation + BRCA2 mutation + TMB-H (1)

BRCA2 deletion + ATM mutation (1)

BRCA2 mutation + AKR1C3 overexpression (1)

BRCA2 mutation + ER positive (1)

BRCA2 mutation + ER positive + PGR positive (1)

BRCA2 mutation + RB1 deletion (1)

BRCA2 mutation + TMB-H (1)

BRCA2 mutation + TMB-L (1)

HR positive + BRCA2 mutation + PALB2 mutation (1)

ER positive + BRCA2 mutation (0)

›

BRCA2 overexpression	Estrogen Receptor Positive Breast Cancer	BRCA2 overexpression	Estrogen Receptor Positive Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
BRCA2 overexpression	Biliary Tract Cancer	BRCA2 overexpression	Biliary Tract Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3